THE EFFECT OF AURANOFIN AND SULFASALAZINE THERAPY ON CIRCULATING LEVELS OF INTERLEUKIN-6 IN RHEUMATOID-ARTHRITIS PATIENTS

被引：2

作者：

CRILLY, A ^{[1
]}

CAPELL, HA ^{[1
]}

WATSON, J ^{[1
]}

MADHOK, R ^{[1
]}

机构：

[1] UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,CTR RHEUMAT DIS,GLASGOW G31 2ER,LANARK,SCOTLAND

来源：

CLINICAL RHEUMATOLOGY | 1995年 / 14卷 / 05期

关键词：

RHEUMATOID ARTHRITIS; AURANOFIN; SULFASALAZINE; IL-6;

D O I：

10.1007/BF02208155

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum levels of interleukin 6 (IL-6), primarily a macrophage derived cytokine and soluble interleukin 2 receptor (sIL-2R), a marker of lymphocyte activation are elevated in rheumatoid arthritis (RA), We have found that the second line drugs auranofin (AUR) and sulphasalazine (SASP) do not significantly alter circulating levels of sIL-2R implying that these durgs do not influence lymphocyte activity, The effect of AUR and SASP on IL-6 is not established, In RA patients we have investigated the effect of these second line agents on serum IL-6 levels, Using the B9 bioassay, serum IL-6 was sequentially measured at 0 and 12 weeks in RA patients treated with auranofin (n=26) or sulphasalazine (n=20), Clinical and laboratory indices of disease activity were also assessed, In patients receiving either AUR or SASP, serum IL-6 was significantly reduced, This reduction was parallelled by improvement in clinical indices of disease activity, AUR and SASP significantly reduce serum IL-6 levels in RA patients receiving these treatments, Combining one of these agents with a drug that also influences sIL-2R may be a more rational approach to combining second line therapy in RA.

引用

页码：561 / 565

页数：5

共 25 条

[1]

Pitzalis C., Kingsley G., Murphy J., Panayi G., Abnormal distribution of the helper-inducer suppressor-inducer T lymphocyte subsets in the rheumatoid joint, Clin Immunol Immunopathol, 45, pp. 252-258, (1987)

[2]

Schwartz R.H., A cell culture model for T lymphocyte clonal anergy, Science, 248, pp. 1349-1356, (1990)

[3]

Rubin L.A., Nelson D.L., The soluble interleukin 2 receptor: biology, function and clinical application, Ann Internal Med, 113, pp. 619-627, (1990)

[4]

Rubin L.A., Jay G., Nelson D.L., The released interleukin 2 receptor binds interleukin 2 efficiently, J Immunol, 137, pp. 3841-3844, (1986)

[5]

Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L., Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro, J Immunol, 135, pp. 3172-3177, (1985)

[6]

Kingsley G., Pitzalis C., Panayi G.S., Immunogenetic and cellular immune mechanisms in rheumatoid arthritis: relevance to new therapeutic strategies, Br J Rheumatol, 29, pp. 58-64, (1990)

[7]

Firestein G.S., Zvaifler N.J., How important are T cells in chronic rheumatoid synovitis, Arthritis Rheum, 33, pp. 768-773, (1990)

[8]

Sanz I., Alboukrek D., Treatment of rheumatoid arthritis, Rheumatoid Arthritis, pp. 99-184, (1991)

[9]

Porter D., Madhok R., Hunter J.A., Capell H.A., Prospective trial comparing the use of sulphasalazine and auranofin as second line agents in patients with rheumatoid arthritis, Ann Rheum Dis, 51, pp. 461-464, (1992)

[10]

Arnett F.C., Edworthy S.M., Bloch D.A., Et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, 31, pp. 315-324, (1988)

← 1 2 3 →